Huge thank you to @MetastaticOdds Josh Newby for the inclusion of and generosity to advocates. Now, to teach him to herd cats (aka attendees!) #6thMBCC

Michael Barrett, PhD, at @MayoClinic talks about genomic drivers of the immune microenvironment. Instead of “bench to bedside”, research should be bedside to bench to bedside - let clinical determinants inform the basic research, then refine it in translational studies. #6thMBCC

Cool thing about lasofoxifene: less vaginal dryness!! #6thMBCC

Dr Haddad of @MayoCancerCare spoke about lasofoxifene, a new generation SERM that has shown promising results in animal models and has been fast tracked by @FDAOncology. ELAINE trial just opened and first pt enrolled today #6thMBCC...

Dr Tufia Haddad: only about half of ER+ MBC are responsive to endocrine therapy. We need to understand resistance - and early vs late development of resistance #6thMBCC

Shirley Mertz of the @mbcalliance reminds us that we patients can urge our doctors to do genetic (what we’re born with) and genomic (the DNA of our tumor) testing. There are barriers like who pays, not part of @NCCN guidelines. #6thMBCC

In @meburkard’s #Outlier study the only habit that was statistically significant between those that have lived 10+ years after first BC dx (early stage OR MBC) was those that are 10+ years drink more 🍷 🍺 🍸 #6thMBCC

Which brings me to soapbox #347: every advanced/metastatic cancer patient should have NGS, if not to decide on a treatment for that individual then to inform the direction of future research. #6thMBCC

.@meburkard explains how they have been able to scale up NGS (next generation sequencing - genomic testing) and clinical trials in #Wisconsin. They’ve found actionable mutations (either approved or in trials) in 1/3 of those tested thus far #6thMBCC

Preliminary Results The Outliers study staff are so thankful to the upwards o...

Ok, it’s not exceptional responders it’s outliers that @meburkard is studying. Here’s a link #6thMBCC
https://outliers.cancer.wisc.edu/preliminary-results/

Page not found | Department of Medicine, University of Wi... The Department of Medicine advances the health of the peo...

Now up @meburkard of @UWCarbone who is doing a study of exceptional responders. Here’s more about him #6thMBCC
www.medicine.wisc.edu/people-search/people/sta...

403 Forbidden

Did I beat @ihatebreastcanc in posting info about @GhajarLab?? #6thMBCC
www.fredhutch.org/en/faculty-lab-directory...

Kudos to @GhajarLab for acknowledging his advocates @TPollastro and @SeagoCoyle in this first slide #6thMBCC

Another super interesting abstract by Dr Julia Ljubimova using nanoparticles engineered to penetrate the BBB, attach to HER2+ or EGFR expressing cells, and light up on MRI. Can differentiate whether lesion is necrosis or progression. MOUSE study at this point #6thMBCC

And because she is on twitter we can follow Dr Ertz-Archambault! I hope she keeps us updated when this pilot study begins to enroll. @ErtzNatalie #6thMBCC

Adaptive therapy: Sometimes the dose will be decreased if tumor responds, sometimes increased if response suboptimal. If excellent response will give a treatment break, restart if/when progression. Pilot study in MBC coming @ErtzNatalie #6thMBCC

Interesting abstract presentation by @ErtzNatalie: with MTD (max tolerated dose) we eliminate cells sensitive to the treatment, leaving resistant cells to grow. Adaptive therapy (lower dose, tx breaks) preserves some sensitive cells that keep the resistant cells in check #6thMBCC

In order to successfully treat mets we need to understand not only DNA mutations but also RNA, proteins, the immune microenvironment. #6thMBCC

Are cancer stem cells the root of all evil? Maybe - this question has been asked for over a decade (this image is from an article in 2008) #6thMBCC

Differences in the microenvironment in different tissues can influence what subtypes (and subtypes of subtypes) go where. #6thMBCC

Oops, it’s @bcmhouston #6thMBCC

We need to understand the metastatic tumor microenvironment, including the immune microenvironment, which may provide new therapeutic opportunities. Jeff Rosen, PhD of @Baylor #6thMBCC

.@itsnot_pink imploring the researchers in the room to work with advocates “you know breast cancer, but I know what it is like to live with #metastaticbreastcancer” #6thMBCC

Julia @itsnot_pink opening up the 2nd day of the @MetastaticOdds #6thMBCC

Antibody-drugs conjugated (ADCs) like TDM1 (Kadcyla) and the still under study DS8201 are the smart bombs of cancer therapy. @hoperugo’s pts on DS8201 are having great response. #6thMBCC

Clinical trials are being designed to be more nimble, smaller, triaged by biomarkers, mutations. @hoperugo #6thMBCC

Always love seeing my oncologist extraordinaire, @hoperugo, at conferences #6thMBCC

#MBCConnect 2.0 will have a trial matching component - it’s like the Tinder of #clinicaltrials: swipe right if you like the trial, swipe left to dismiss! #6thMBCC

#MBC patient and advocate @TPollastro and Dr Tim Pluard updating the audience about @mbcalliance ‘s #MBCconnect app #6thMBCC

Danny Welch summarizes a lively discussion: in the lab we need better models of all the subtypes of #MBC; in the clinic we need navigation; politically we have to convince agencies to allow trials to be brought to patients - and we #advocates can help with all of this #6thMBCC